Non-squamous Cell Non-small Cell Lung Cancer Clinical Trial
Official title:
to Evaluate SCT510 Compared to Avasitin Respectively Combined Paclitaxel and Carboplatin First-line Treatment of Locally Advanced and Metastatic or Recurrent Squamous Cell Non-small Cell Lung Cancer Efficacy and Safety
To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of locally advanced metastatic or recurrent squamous cell non-small cell lung cancer.
A randomized, double-blind, parallel-controlled, multicenter phase 3 clinical trial.
560 patients with non-resectable locally advanced, metastatic or recurrent non-squamous cell
non-small cell lung cancer (NSCLC) were randomly divided into two groups (SCT510 group and
bevacizumab group) at a 1:1 ratio, and the treatment included combination chemotherapy and
maintenance treatment, followed by follow-up.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01673867 -
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
|
Phase 3 | |
| Recruiting |
NCT03790228 -
Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC
|
Phase 1 | |
| Recruiting |
NCT03778138 -
Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC
|
Phase 2 |